Literature DB >> 2199362

Sequelae to acromegaly: reversibility with treatment of the primary disease.

S A Lieberman1, A R Hoffman.   

Abstract

Acromegalic patients suffer from a number of cardiovascular, metabolic, and rheumatologic problems, and they may also have an increased incidence of malignancy. We reviewed the literature concerning the reversibility of acromegalic complications. Hypertension, myocardial hypertrophy, left ventricular dysfunction and some rheumatologic abnormalities often continue despite successful treatment of the acromegaly. In contrast, glucose intolerance, soft tissue changes, and carpal tunnel syndrome usually resolve when the acromegaly is cured. Studies of the incidence and mortality of cancer in acromegaly are conflicting, but several suggest an increased incidence of colorectal cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2199362     DOI: 10.1055/s-2007-1004910

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

Review 1.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 2.  Acromegaly. Recognition and treatment.

Authors:  C A Jaffe; A L Barkan
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

3.  Acromegaly: an epidemiological study.

Authors:  J Etxabe; S Gaztambide; P Latorre; J A Vazquez
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

4.  Comparing the Behavioural Effects of Exogenous Growth Hormone and Melatonin in Young and Old Wistar Rats.

Authors:  Pere Barceló; Cristina Nicolau; Antoni Gamundí; Maria A Fiol; Jesús A F Tresguerres; Mourad Akaârir; Rubén V Rial
Journal:  Oxid Med Cell Longev       Date:  2016-12-05       Impact factor: 6.543

Review 5.  The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Authors:  Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.